# Safety and Tolerability of Subretinal OPGx-RDH12-1001 for LCA-Associated Inherited Retinal Degeneration (LCA-IRD)

> **NCT07681778** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Opus Genetics, Inc** · enrollment: 10 (estimated)

## Conditions studied

- Leber Congenital Amaurosis
- Leber Congenital Amaurosis (LCA)

## Interventions

- **DRUG:** OPGx-RDH12

## Key facts

- **NCT ID:** NCT07681778
- **Lead sponsor:** Opus Genetics, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-09-01
- **Primary completion:** 2032-12
- **Final completion:** 2034-07
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2026-07-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07681778

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07681778, "Safety and Tolerability of Subretinal OPGx-RDH12-1001 for LCA-Associated Inherited Retinal Degeneration (LCA-IRD)". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07681778. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*